BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 32063918)

  • 1. A Novel Prognostic Index Based on Alternative Splicing in Papillary Renal Cell Carcinoma.
    Wu Z; Liu J; Sun R; Chen D; Wang K; Cao C; Xu X
    Front Genet; 2019; 10():1333. PubMed ID: 32063918
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of novel prognostic alternative splicing signature in papillary renal cell carcinoma.
    Duan Y; Zhang D
    J Cell Biochem; 2020 Jan; 121(1):672-689. PubMed ID: 31407370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. hsa-mir-3199-2 and hsa-mir-1293 as Novel Prognostic Biomarkers of Papillary Renal Cell Carcinoma by COX Ratio Risk Regression Model Screening.
    Luo W; Wang L; Luo MH; Huang YZ; Yang H; Zhou Y; Jia HT; Wang XX
    J Cell Biochem; 2017 Oct; 118(10):3488-3494. PubMed ID: 28338236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic Signature of Alternative Splicing Events in Bladder Urothelial Carcinoma Based on Spliceseq Data from 317 Cases.
    He RQ; Zhou XG; Yi QY; Deng CW; Gao JM; Chen G; Wang QY
    Cell Physiol Biochem; 2018; 48(3):1355-1368. PubMed ID: 30048970
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alternative Splicing Events and Splicing Factors Are Prognostic in Adrenocortical Carcinoma.
    Lv J; He Y; Li L; Wang Z
    Front Genet; 2020; 11():918. PubMed ID: 33101358
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of Survival-Associated Alternative Splicing Signatures in Lung Squamous Cell Carcinoma.
    Liu Y; Jia W; Li J; Zhu H; Yu J
    Front Oncol; 2020; 10():587343. PubMed ID: 33117720
    [No Abstract]   [Full Text] [Related]  

  • 7. Novel insights into clear cell renal cell carcinoma prognosis by comprehensive characterization of aberrant alternative splicing signature: a study based on large-scale sequencing data.
    Zhang D; Zhang W; Sun R; Huang Z
    Bioengineered; 2021 Dec; 12(1):1091-1110. PubMed ID: 33783315
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of a prognostic alternative splicing signature in oral squamous cell carcinoma.
    Zhang S; Wu X; Diao P; Wang C; Wang D; Li S; Wang Y; Cheng J
    J Cell Physiol; 2020 May; 235(5):4804-4813. PubMed ID: 31637730
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of alternative splicing events in endometrial cancer prognosis.
    Liu J; Mi C; Long W; Sun T
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2021 Jul; 46(7):680-688. PubMed ID: 34382583
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic Value and Potential Role of Alternative mRNA Splicing Events in Cervical Cancer.
    Shao XY; Dong J; Zhang H; Wu YS; Zheng L
    Front Genet; 2020; 11():726. PubMed ID: 32793282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comprehensive Analysis of Alternative Splicing Signature in Gastric Cancer Prognosis Based on The Cancer Genome Atlas (TCGA) and SpliceSeq Databases.
    Cheng X; Li X; Gu Y; Zhou L; Tang J; Dai X; Jiang H; Huang Y; Zhang Y; Xu T; Liu Z; Zhao Q
    Med Sci Monit; 2020 Nov; 26():e925772. PubMed ID: 33219199
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systematic analysis of alternative splicing signature unveils prognostic predictor for kidney renal clear cell carcinoma.
    Song J; Liu YD; Su J; Yuan D; Sun F; Zhu J
    J Cell Physiol; 2019 Dec; 234(12):22753-22764. PubMed ID: 31140607
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic Signatures of Alternative Splicing Events in Esophageal Carcinoma Based on TCGA Splice-Seq Data.
    Ye P; Yang Y; Zhang L; Zheng G
    Front Oncol; 2021; 11():658262. PubMed ID: 34676158
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systematic analysis of the relationship between ovarian cancer prognosis and alternative splicing.
    Zhang D; Zou D; Deng Y; Yang L
    J Ovarian Res; 2021 Sep; 14(1):120. PubMed ID: 34526089
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of Prognostic and Metastatic Alternative Splicing Signatures in Kidney Renal Clear Cell Carcinoma.
    Meng T; Huang R; Zeng Z; Huang Z; Yin H; Jiao C; Yan P; Hu P; Zhu X; Li Z; Song D; Zhang J; Cheng L
    Front Bioeng Biotechnol; 2019; 7():270. PubMed ID: 31681747
    [No Abstract]   [Full Text] [Related]  

  • 16. Genome-wide mutation profiling and related risk signature for prognosis of papillary renal cell carcinoma.
    Zhang C; Zheng Y; Li X; Hu X; Qi F; Luo J
    Ann Transl Med; 2019 Sep; 7(18):427. PubMed ID: 31700863
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long non-coding RNAs as prognostic biomarkers in papillary renal cell carcinoma.
    Yang F; Song Y; Ge L; Zhao G; Liu C; Ma L
    Oncol Lett; 2019 Oct; 18(4):3691-3697. PubMed ID: 31516581
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of Prognostic Alternative Splicing Signature in Breast Carcinoma.
    Zhang D; Duan Y; Cun J; Yang Q
    Front Genet; 2019; 10():278. PubMed ID: 30984247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Profiles of prognostic alternative splicing signature in hepatocellular carcinoma.
    Wu F; Chen Q; Liu C; Duan X; Hu J; Liu J; Cao H; Li W; Li H
    Cancer Med; 2020 Mar; 9(6):2171-2180. PubMed ID: 31975560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of alternative splicing events and prognostic signatures in breast cancer.
    Han P; Zhu J; Feng G; Wang Z; Ding Y
    BMC Cancer; 2021 May; 21(1):587. PubMed ID: 34022836
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.